

Commentary on Glycemic Control in Diabetic Patients

Michael Pignone*

Department of medicine, The University of North Carolina, United State of America

Corresponding Author*

Michael Pignone

Department of medicine, The University of North Carolina, United State of America

Email: pignonemichael@yahoo.com

Copyright: © 2022 Pignone M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 01-Apr-2022, Manuscript No. jdm-22-17190; **Editor assigned:** 04-Apr-2022, PreQC No: jdm-22-17190(PQ); **Reviewed:** 18-Apr-2022, QC No. Jdm-22-17190; **Revised:** 20-Apr-2022, Manuscript No. Jdm-22-17190(R); **Published:** 25-Apr-2022, DOI: 10.35248/2155-6156.1000931

Commentary

Most of the food we eat is broken down into sugar (also called glucose) and released into our bloodstream. When your blood sugar goes up, it signals your pancreas to release insulin. Diabetes is a chronic (long-lasting) health condition that affects how your body turns food into energy [1].

Dixon and colleagues are to be commended for conducting a randomized trial to help us better understand the efficacy of laparoscopic gastric banding as a means of helping patients reduce their weight and improve remission of diabetes. They found that laparoscopic surgery plus conventional treatment was substantially more effective than conventional treatment alone throughout 2 years of follow-up. The combined intervention produced greater weight loss and greatly increased the likelihood of "diabetes remission." Adverse events were relatively uncommon, and other secondary outcomes, including presence of metabolic syndrome and the use of antihypertensive medications, were also improved [2]. These results suggest that laparoscopic gastric banding may offer important benefits for obese patients with newly diagnosed diabetes.

These promising results should be viewed in the context of some important limitations. First, this trial was small, with only 60 total participants. Because the trial produced large effects, the small size did not affect its ability to determine efficacy. The limited number of participants, however, raises questions about the generalizability of the findings. Participants were volunteers and were required to complete a run-in phase before randomization. Enrolled patients had BMIs between 30 and 40 kg/m², so we cannot be sure that those with lesser or greater degrees of overweight or obesity would derive similar benefits, nor can we determine whether the effects would be the same for patients with "pre-diabetes" or longer standing duration of disease. Perhaps more importantly, the surgical team had extensive experience with the laparoscopic gastric banding and had low rates of complications and no surgical deaths. Ensuring safe surgical outcomes is necessary if such procedures are to be considered for patients such as those enrolled in this trial [3].

Randomization produced relatively equal groups with respect to important comorbid conditions, and there were relatively few participants lost to follow-up. Intention-to-treat analyses were appropriately conducted, and we can have good confidence that the results obtained did not suffer from measurement error.

The results of this trial help confirm anecdotal and observational data suggesting improvements in many metabolic parameters after bariatric surgery [4]. It will be important to replicate this trial among a larger, more diverse set of centers and patients to test its generalizability. If these results

are replicated, more focused attention will need to be paid to helping patients consider this option when examining potentially effective therapies for obesity-related illnesses [5].

Design

A randomized controlled trial comparing a conventional lifestyle change intervention to conventional management plus laparoscopic adjustable gastric banding for the outcomes of "diabetes regression," defined as fasting glucose < 126 mg/dl and hemoglobin A1c (A1C) < 6.2% while using no glucose-controlling medications.

Subject

Sixty patients with a BMI of 30-40 kg/m² and recently (within 2 years) diagnosed diabetes.

Methods

Eligible participants were 20–60 years of age, had type 2 diabetes diagnosed within 2 years, and had no evidence of impaired renal function or diabetic retinopathy. Potential participants completed a 3-month run-in period that included efforts to optimize their diabetes treatment. Those completing the run-in period were randomized, and no attempt was made to blind patients or providers to their intervention status. Those assigned to conventional therapy had access to a team of providers and were seen at least every 6 weeks. They were counseled to follow a low-fat, low-glycemic-index diet and to engage in moderate physical activity. Those in the intervention group received similar conventional treatment, underwent laparoscopic placement of the adjustable gastric band, and had visits every 4-6 weeks. The main outcome of regression of diabetes was assessed after 2 years; secondary measures included A1C, weight, and lipid levels.

Results

Results of the 60 enrolled patients, 55 completed 2-year follow-up. Participants in the surgical intervention group were more likely to achieve diabetes remission than those in the conventional treatment control arm (73 vs. 13%, relative risk 5.5, 95% CI 2.2, 14.0). Weight loss was also greater in the surgical group (20.7 vs. 1.7% for the conventional treatment group). Remission was well correlated with weight loss (R² = 0.46). Four patients in the surgical arm had important adverse events (one postsurgical wound infection treated with intravenous antibiotics; two cases of gastric pouch enlargement requiring reoperation; and one patient who had "persistent eating difficulties" and required band removal).

Conclusion

Obese adults with recent onset of diabetes who were assigned to receive laparoscopic gastric banding plus conventional therapy were more likely to achieve diabetes remission than those assigned to conventional treatment alone.

References

1. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, et al. (1976) Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. *N Engl J Med* 295:417-420.
2. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, et al. (2019) Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. *N Engl J Med* 381:603-613.
3. Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, et al. (2021) Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. *Cardiovasc Diabetol* 20:14.

4. Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. *Diabetes Technol Ther* 19(Suppl. 3): S25-S37.
5. Dovc K, Battelino T (2020) Closed-loop insulin delivery systems in children and adolescents with type 1 diabetes. *Expert Opin Drug Deliv* 17:157-166.